Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

265

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

January 31, 2027

Study Completion Date

December 31, 2029

Conditions
Bronchopulmonary Dysplasia
Interventions
BIOLOGICAL

Endotracheopulmonary Instillation, Suspension

"The endotracheal administration can be either by endotracheal tube instillation using a 5 French end-hole catheter or by endotracheal tube instillation using the secondary lumen of a dual lumen endotracheal tube.~The dose is adjusted to body weight and the endotracheal administration will be performed in an already intubated newborn infant."

Trial Locations (8)

1200

NOT_YET_RECRUITING

Cliniques Universitaires Saint-Luc (UCLouvain), Brussels

4000

NOT_YET_RECRUITING

Clinique CHC Montlégia, Liège

6000

NOT_YET_RECRUITING

ISPPC CHU Charleroi, Charleroi

35128

RECRUITING

Unità di Fase I della UOC Terapia Intensiva e Patologia Neonatale, Assistenza Neonatale (TINI) dell'Azienda Ospedale Università di Padova, Padua

Unknown

ACTIVE_NOT_RECRUITING

AOU Careggi, Florence

RECRUITING

IRCCS Instituto Giannina Gaslini, Genova

ACTIVE_NOT_RECRUITING

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

NOT_YET_RECRUITING

AOU Policlinico di Modena, Modena

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EXO Biologics S.A.

INDUSTRY

NCT06279741 - Safety and Efficacy of MSC-EVs in the Prevention of BPD in Extremely Preterm Infants | Biotech Hunter | Biotech Hunter